Alveo Technologies Announces Open Platform Strategy. Click here to read the news.
ADVANCING THE IMPACT OF MOLECULAR DIAGNOSTICS

What We Do

At Alveo we understand the importance of access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo’s agile and dynamic molecular diagnostic platform, be.well™, can be adapted to detect a wide range of diseases, bacteria, and other pathogens that threaten public health, across all modalities. We believe increased access to real-time test results will transform the way individuals, healthcare providers and public health professionals identify and manage infectious diseases. With be.well™, we will Know Sooner, Act Faster™.

Who We Are

We are team-oriented scientists, innovators, data geeks, and entrepreneurs who share a passion for making a positive impact on humanity. We believe that every problem has a clear solution—when you apply the right knowledge and are open to different perspectives.

We are proud to be Alveo. We’re dedicated to tackling challenges and improving lives.

Leadership

Shaun Holt
Shaun Holt headshot

Shaun Holt serves as Chairman of the Board and Chief Executive Officer of Alveo Technologies. Previously, Shaun served as Chief Operating Officer of Atonarp, Inc., a Celesta Capital-backed optical- and mass-spectrometry instrumentation company. Prior to Atonarp, as Chief Financial Officer for Berkeley Lights, Inc., Shaun led the digital cell biology company through its $205 million initial public offering. In addition, Shaun held numerous finance leadership positions during his seven-year tenure at Illumina throughout its exponential growth phase. He brings more than 20 years of operational and financial leadership experience across various technology and life sciences companies from start-ups to large-capitalization companies. Shaun is an advisor to Celesta Capital and serves on the Board of Directors of Prellis Biologics.
Erik Tyrrell-Knott, JD
Erik Tyrrell-Knott headshot


As Alveo’s Chief Business and Strategy Officer, Erik Tyrrell-Knott leads business and market development, sales, partnering, and product management efforts, driving the Company’s commercial, partnership, and go-to-market strategies. With more than 20 years of experience in strategic business development for medical device and diagnostic companies ranging from start-ups to mature global corporations, Erik most recently served as Vice President of Business Development at Atonarp, Inc., and previously as Head of Business Development for Thermo Fisher Scientific, and previously as Senior Vice President of Business Development and Product Management at Mesa Biotech prior to its acquisition by Thermo Fisher.

Slava Elagin, PhD, MBA
Slava Elagin headshot

Dr. Slava Elagin brings to Alveo more than 20 years of experience in the in vitro diagnostics and medical devices industry. Previously, Slava held senior executive operations and research and development positions with publicly traded and private companies including MiraVista Diagnostics, Meridian Biosciences, EraGen Biosciences, and Third Wave Technologies. He has led 15 molecular diagnostic product development projects from product concept through U.S. Food & Drug Administration clearances and commercialization and is the author on 12 U.S. patents and three global patents for molecular assays and diagnostics.
Ron Keith
Ron Keith headshot

Ron Keith is a career engineering, manufacturing, and supply chain executive, with over 25 years of experience, and currently serves Alveo Technologies as its Chief Operating Officer. He is the founder and Executive Director of Supply Chain Resources Group, which provides manufacturing and supply chain services in six countries to the world’s leading tech product companies and most promising start-ups, and has consulted on product operations, manufacturing, strategy, and supply chain in 22 different countries for more than 100 companies, including a dozen global Fortune 500 companies.
Mona Patel
Mona Patel headshot


Mona Patel is the Vice President of Clinical Affairs at Alveo Technologies, where she oversees Alveo’s clinical and human factors strategies supporting both registrational and nonregistrational programs. In addition, Mona leads Alveo’s product labeling, user experience (UX), and user interface (UI) initiatives.

Mona joined Alveo with over 20 years of R&D and clinical research experience within the IVD industry. For the past 16 years, she has been strategically defining, designing, and executing clinical programs in support of successful regulatory and commercial strategies for diagnostic companies such as Abbott, Cepheid, and Roche.

Kevin Gunning
Kevin Gunning headshot


Kevin Gunning oversees Alveo’s Quality Management System and holds more than 25 years of experience working in the medical device, pharmaceutical, biotechnology, and clinical laboratory industries.

Kevin has successfully developed, implemented, and managed quality systems for a number of organizations, ranging from fledgling start-ups to established global corporations. He holds a bachelor’s degree in biological sciences from State University of New York at Buffalo and is an ASQ-certified Quality Auditor.

Angie Aquino-Sales
Angie Aquino-Sales headshot


Angie Aquino-Sales serves as Senior Director of People & Culture at Alveo Technologies, where she is focused on human resources strategic planning and organizational design, building HR functions, and designing talent programs for leader and employee development.

Prior to joining Alveo, Angie served at Prologis as a Senior Human Resources Business Partner, at OptiScan Biomedical as Head of HR, and at Tripping.com as Director of HR. Angie has experience working in start-ups and small businesses in a variety of industries. She has held related roles in large organizations including Kaiser Permanente, Blue Shield of California, and McKesson.

Ian Smith
Ian Smith headshot


Ian Smith is a financial executive with over 25 years of controllership experience. His experience includes building and scaling financial operations for high-growth companies, and he has participated in numerous rounds of fundraising, M&A transactions, and public offerings. Prior to joining Alveo, Ian held leadership positions at Blackthorn Therapeutics (now Neumora) and Biomarin.

Mary K. McFillin
Mary K. McFillin headshot


Mary McFillin is a senior global product marketing manager with extensive experience in the point-of-care diagnostics industry, leading strategy, development, and support of in vitro diagnostics medical devices throughout the product life cycle. As a senior product management executive, Mary leads Alveo’s strategic marketing and target market development. She joins Alveo from Thermo Fisher Scientific, Rapid Diagnostic Solutions, where she served as Senior Manager of Product Management. Previously, she held similar positions for Abbott Laboratories and Alere, Inc.

Board of Directors

Shaun Holt
Shaun Holt headshot


Shaun Holt serves as Chairman of the Board and Chief Executive Officer of Alveo Technologies. Previously, Shaun served as Chief Operating Officer of Atonarp, Inc., a Celesta Capital-backed optical- and mass-spectrometry instrumentation company. Prior to Atonarp, as Chief Financial Officer for Berkeley Lights, Inc., Shaun led the digital cell biology company through its $205 million initial public offering. In addition, Shaun held numerous finance leadership positions during his seven-year tenure at Illumina throughout its exponential growth phase. He brings more than 20 years of operational and financial leadership experience across various technology and life sciences companies from start-ups to large-capitalization companies. Shaun is an advisor to Celesta Capital and serves on the Board of Directors of Prellis Biologics.

Michael Marks
Michael Marks headshot


For 40 years, Michael Marks has successfully led and transformed technology companies. He is a founding managing partner at Celesta Capital, where he co-leads the firm. From 2007 to 2019, he was a founding partner at Riverwood Capital Management, a private equity fund specializing in rapidly growing private companies in North America and emerging markets. He was a partner and senior advisor at Kohlberg Kravis Roberts & Co (KKR) in 2006 and 2007. Before KKR, he spent 13 years as Chairman and CEO of Flextronics International Ltd and built the company into one of the largest technology companies in the world.

Who Supports Alveo’s Vision

Alveo’s investors that share and support our vision.